Open,O
Access,O
Technical,O
COVID,O
‐,O
19,NUMBER
:,O
Precautionary,O
Guidelines,O
for,O
Hani,PERSON
B.,O
ALBalawi,O
1,NUMBER
Several,O
coronaviruses,O
can,O
infect,O
humans,O
.,O
and,O
the,O
globally,O
endemic,O
human,O
coronaviruses,O
.,O
HCoV,O
‐,O
229E,O
(,O
human,O
coron,O
‐,O
avirus,O
229E,O
),O
.,O
HCoV,O
‐,O
NL63,O
(,O
human,O
coronavirus,O
NL63,O
),O
.,O
and,O
others,O
.,O
tend,O
to,O
cause,O
mild,O
respiratory,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
.,O
The,O
zoonotic,O
Middle,LOCATION
East,LOCATION
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
‐,O
CoV,O
),O
and,O
severe,O
acute,O
res,O
‐,O
piratory,O
syndrome,O
coronavirus,O
type1,O
(,O
SARS,O
‐,O
CoV1,O
),O
have,O
high,O
fatali,O
‐,O
ty,O
rates,O
.,O
In,O
December,DATE
2019,DATE
.,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
(,O
WHO,O
),O
was,O
was,O
identified,O
in,O
January,DATE
2020,DATE
as,O
a,O
novel,O
coronavirus,O
family,O
.,O
The,O
WHO,O
refers,O
to,O
the,O
virus,O
as,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Within,O
several,DURATION
weeks,DURATION
.,O
the,O
outbreak,O
has,O
become,O
an,O
emergency,O
.,O
and,O
many,O
countries,O
have,O
since,O
been,O
affected,O
.,O
The,O
method,O
of,O
transmission,O
is,O
not,O
yet,O
fully,O
known,O
but,O
is,O
thought,O
to,O
be,O
mainly,O
respiratory,O
.,O
Healthcare,O
providers,O
.,O
particularly,O
oph,O
‐,O
thalmologists,O
.,O
are,O
at,O
high,O
risk,O
of,O
a,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
through,O
unprotected,O
contact,O
with,O
eye,O
secretions,O
during,O
routine,O
ophthalmic,O
examinations,O
that,O
involve,O
the,O
use,O
of,O
direct,O
ophthalmoscopy,O
and,O
slit,O
‐,O
lamp,O
examinations,O
.,O
which,O
are,O
usually,O
performed,O
in,O
a,O
setting,O
that,O
allows,O
for,O
close,O
doctor,TITLE
‐,O
patient,O
contact,O
.,O
In,O
light,O
of,O
these,O
.,O
specific,O
measures,O
are,O
needed,O
from,O
an,O
ophthalmic,O
point,O
of,O
view,O
to,O
control,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
and,O
to,O
protect,O
health,O
care,O
Cate,O
‐,O
gories,O
:,O
Ophthalmology,O
.,O
Preventive,O
Medicine,O
.,O
Infectious,CAUSE_OF_DEATH
Disease,CAUSE_OF_DEATH
Keywords,O
:,O
covid,O
‐,O
19,NUMBER
.,O
conjunctivitis,O
.,O
prevention,O
ophthalmology,O
.,O
ophthalmology,O
.,O
guideline,O
.,O
infection,CAUSE_OF_DEATH
.,O
health,O
care,O
worker,O
safety,O
.,O
corona,O
pandemic,O
.,O
coronavirus,O
guidelines,O
.,O
coronavirus,O
ALBalawi,O
.,O
This,O
is,O
an,O
open,O
access,O
unrestricted,O
use,O
.,O
distribution,O
.,O
and,O
repro,O
‐,O
duction,O
in,O
any,O
medium,O
.,O
provided,O
A,O
33,NUMBER
‐,O
year,DURATION
‐,O
old,O
ophthalmologist,TITLE
.,O
Dr.,O
Li,PERSON
Wenliang,PERSON
.,O
was,O
the,O
first,ORDINAL
to,O
raise,O
the,O
alarm,O
about,O
a,O
cluster,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
‐,O
like,O
pneumonia,CAUSE_OF_DEATH
cases,O
late,DATE
December,DATE
2019,DATE
at,O
Wuhan,CITY
City,LOCATION
.,O
China,COUNTRY
.,O
Regrettably,O
.,O
that,O
warn,O
‐,O
ing,O
was,O
not,O
taken,O
seriously,O
.,O
Following,O
that,O
.,O
Dr.,O
Li,PERSON
returned,O
to,O
work,O
and,O
.,O
unfortunately,O
.,O
contracted,O
the,O
virus,O
from,O
an,O
asympto,O
‐,O
matic,O
glaucoma,O
patient,O
in,O
early,DATE
January,DATE
.,O
Later,O
on,O
.,O
Dr.,O
Li,PERSON
passed,O
away,O
.,O
leaving,O
behind,O
a,O
child,O
and,O
a,O
wife,O
.,O
who,O
is,O
pregnant,O
.,O
and,O
opened,O
the,O
doors,O
and,O
discussions,O
about,O
the,O
risk,O
of,O
infection,CAUSE_OF_DEATH
among,O
ophthalmologists,O
.,O
A,O
survey,O
study,O
by,O
Nair,PERSON
and,O
colleagues,O
re,O
‐,O
ported,O
that,O
the,O
majority,O
of,O
ophthalmologists,O
in,O
India,COUNTRY
(,O
59.1,PERCENT
%,PERCENT
),O
felt,O
that,O
ophthalmologists,O
were,O
potentially,O
at,O
a,O
higher,O
risk,O
of,O
contracting,O
COVID,O
‐,O
19,NUMBER
as,O
compared,O
to,O
other,O
specialties,O
while,O
exam,O
‐,O
ining,O
patients,O
[,O
1,NUMBER
],O
.,O
In,O
fact,O
.,O
ophthalmologists,O
are,O
at,O
high,O
risk,O
of,O
contracting,O
the,O
COVID,O
‐,O
19,NUMBER
virus,O
through,O
unprotected,O
eye,O
contact,O
with,O
secretions,O
during,O
routine,O
ophthalmic,O
examinations,O
with,O
di,O
‐,O
rect,O
ophthalmoscopy,O
and,O
slit,O
‐,O
lamp,O
examinations,O
.,O
which,O
are,O
usually,O
performed,O
in,O
a,O
setting,O
that,O
has,O
close,O
doctor,TITLE
‐,O
patient,O
contact,O
.,O
On,O
December,DATE
31,DATE
.,DATE
2019,DATE
.,O
the,O
WHO,ORGANIZATION
was,O
notified,O
by,O
China,COUNTRY
about,O
an,O
out,O
‐,O
break,O
of,O
pneumonia,CAUSE_OF_DEATH
with,O
an,O
initially,O
unknown,O
etiology,O
in,O
Wuhan,CITY
city,O
in,O
Hubei,STATE_OR_PROVINCE
province,LOCATION
.,O
In,O
January,DATE
2020,DATE
.,O
the,O
causative,O
organism,O
was,O
identified,O
as,O
a,O
novel,O
member,O
of,O
the,O
coronavirus,O
family,O
.,O
Ini,O
‐,O
tially,O
tentatively,O
named,O
2019,DATE
novel,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
and,O
named,O
SARS,O
‐,O
CoV,O
‐,O
Albalawi,O
H,O
B,O
(,O
June,DATE
25,DATE
.,DATE
2020,DATE
),O
COVID,O
‐,O
19,NUMBER
:,O
Precau,O
‐,O
tionary,O
Guidelines,O
for,O
Ophthalmologists,O
.,O
Cureus,O
12,NUMBER
(,O
6,NUMBER
),O
:,O
type,O
2,NUMBER
by,O
the,O
International,ORGANIZATION
Committee,ORGANIZATION
of,ORGANIZATION
Taxonomy,ORGANIZATION
of,ORGANIZATION
Viruses,ORGANIZATION
(,O
ICTV,ORGANIZATION
),O
.,O
this,O
virus,O
is,O
the,O
cause,O
of,O
the,O
disease,CAUSE_OF_DEATH
named,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
To,O
date,O
.,O
COVID,O
‐,O
19,NUMBER
has,O
already,O
confirmed,O
to,O
have,O
af,O
‐,O
fected,O
over,O
5.000.000,NUMBER
people,O
and,O
caused,O
over,O
300.00,NUMBER
deaths,O
world,O
‐,O
wide,O
.,O
spanning,O
205,NUMBER
countries,O
in,O
South,LOCATION
East,LOCATION
Asia,CITY
.,O
Europe,LOCATION
.,O
North,PERSON
America,COUNTRY
.,O
Australia,COUNTRY
.,O
and,O
the,O
Middle,LOCATION
East,LOCATION
and,O
led,O
to,O
huge,O
public,O
health,O
challenges,O
[,O
2,NUMBER
],O
.,O
The,O
transmission,O
route,O
of,O
COVID,O
‐,O
19,NUMBER
is,O
not,O
yet,O
fully,O
known,O
but,O
it,O
is,O
thought,O
to,O
be,O
mainly,O
respiratory,O
.,O
It,O
is,O
even,O
more,O
overwhelming,O
that,O
many,O
infected,O
persons,O
showed,O
no,O
ap,O
‐,O
parent,O
respiratory,O
symptoms,O
and,O
presented,O
with,O
non,O
‐,O
respiratory,O
manifestations,O
.,O
including,O
conjunctivitis,O
in,O
the,O
ocular,O
tissue,O
[,O
3,NUMBER
],O
and,O
diarrhea,O
in,O
the,O
gastrointestinal,O
system,O
[,O
4,NUMBER
],O
.,O
COVID,O
‐,O
19,DATE
may,DATE
spread,O
through,O
the,O
eyes,O
mucous,O
membrane,O
via,O
indirect,O
contact,O
with,O
droplets,O
.,O
The,O
variable,O
presentation,O
of,O
the,O
disease,CAUSE_OF_DEATH
makes,O
trans,O
‐,O
mission,O
via,O
contact,O
.,O
especially,O
for,O
health,O
care,O
providers,O
like,O
ophthalmologists,O
.,O
possible,O
.,O
Since,O
the,O
outbreak,O
.,O
more,O
than,O
3.300,NUMBER
healthcare,O
professionals,O
having,O
been,O
infected,O
.,O
with,O
44,NUMBER
deaths,O
.,O
including,O
one,NUMBER
ophthalmologist,TITLE
.,O
Multiple,O
comprehensive,O
recommenda,O
‐,O
tions,O
by,O
the,O
American,ORGANIZATION
Academy,ORGANIZATION
of,ORGANIZATION
Ophthalmology,ORGANIZATION
(,O
AAO,ORGANIZATION
),O
[,O
5,NUMBER
],O
and,O
a,O
well,O
‐,O
designed,O
study,O
from,O
Hong,CITY
Kong,CITY
[,O
6,NUMBER
],O
were,O
announced,O
helping,O
ophthalmologists,O
for,O
safe,O
provide,O
instructions,O
and,O
uniform,O
guide,TITLE
‐,O
lines,O
.,O
This,O
paper,O
aimed,O
to,O
provide,O
an,O
evidence,O
‐,O
based,O
recommenda,O
‐,O
tion,O
.,O
Subsequent,O
information,O
about,O
the,O
nature,O
of,O
COVID,O
‐,O
19,DATE
may,DATE
change,O
these,O
recommendations,O
in,O
the,DATE
future,DATE
.,O
In,O
light,O
of,O
these,O
.,O
specific,O
measures,O
are,O
needed,O
from,O
an,O
ophthalmic,O
point,O
of,O
view,O
to,O
control,O
the,O
COVID,O
‐,O
019,NUMBER
outbreak,O
and,O
to,O
protect,O
health,O
care,O
Techni,O
‐,O
cal,O
Report,O
Before,O
encountering,O
patients,O
during,O
a,O
pandemic,O
lock,O
‐,O
down,O
Because,O
of,O
the,O
disease,CAUSE_OF_DEATH
’s,O
contagiousness,O
and,O
way,O
of,O
spread,O
.,O
it,O
is,O
better,O
and,O
safe,O
to,O
keep,O
nonurgent,O
patients,O
away,O
from,O
the,O
hospital,O
during,O
the,O
pandemic,O
period,O
.,O
The,O
priority,O
should,O
be,O
on,O
how,O
to,O
reduce,O
the,O
risk,O
of,O
COVID,O
‐,O
19,NUMBER
virus,O
transmission,O
from,O
human,O
to,O
human,O
and,O
the,O
rate,O
of,O
new,O
case,O
development,O
.,O
Then,O
.,O
we,O
flatten,O
the,O
curve,O
and,O
not,O
overwhelm,O
the,O
health,O
services,O
and,O
limited,O
sup,O
‐,O
ply,O
of,O
hospital,O
beds,O
.,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
beds,O
.,O
ventila,O
‐,O
tors,O
.,O
and,O
others,O
.,O
Second,ORDINAL
.,O
direct,O
all,O
disposable,O
medical,O
supplies,O
and,O
focus,O
them,O
on,O
hospitals,O
where,O
they,O
are,O
most,O
needed,O
[,O
5,NUMBER
],O
.,O
Therefore,O
.,O
all,O
non,O
‐,O
urgent,O
routine,O
follow,O
‐,O
up,O
and,O
surgeries,O
like,O
mild,O
nonproliferative,O
diabetic,O
retinopathy,O
or,O
routine,O
scheduled,O
cataract,O
surgery,CAUSE_OF_DEATH
should,O
be,O
postponed,O
.,O
It,O
is,O
even,O
better,O
if,O
pa,O
‐,O
tients,O
can,O
be,O
sent,O
text,O
messages,O
or,O
called,O
to,O
discuss,O
the,O
need,O
to,O
reschedule,O
their,O
appointment,O
or,O
a,O
public,O
announcement,O
to,O
cancel,O
all,O
routine,O
follow,O
‐,O
up,O
visits,O
and,O
surgeries,O
.,O
in,O
order,O
to,O
minimize,O
all,O
non,O
‐,O
urgent,O
cases,O
coming,O
to,O
the,O
eye,O
clinic,O
or,O
hospital,O
[,O
5,NUMBER
],O
.,O
A,O
three,NUMBER
‐,O
stage,O
control,O
measure,O
to,O
reduce,O
the,O
transmission,O
of,O
the,O
virus,O
in,O
the,O
ophthalmology,O
department,O
in,O
Hong,CITY
Kong,CITY
was,O
based,O
on,O
text,O
messaging,O
to,O
reschedule,O
refill,O
visits,O
[,O
6,NUMBER
],O
;,O
a,O
triage,O
to,O
iden,O
‐,O
tify,O
patients,O
with,O
fever,CAUSE_OF_DEATH
.,O
conjunctivitis,O
.,O
and,O
respiratory,O
symp,O
‐,O
toms,O
;,O
asking,O
those,O
who,O
recently,DATE
traveled,O
to,O
areas,O
infected,O
with,O
the,O
virus,O
to,O
postpone,O
their,O
ophthalmology,O
visits,O
for,O
14,DURATION
days,DURATION
;,O
and,O
the,O
avoidance,O
of,O
micro,O
‐,O
aerosol,O
generating,O
procedures,O
.,O
nasal,O
en,O
‐,O
doscopy,O
.,O
and,O
operations,O
under,O
general,TITLE
anesthesia,O
.,O
In,O
addition,O
.,O
infection,CAUSE_OF_DEATH
control,O
was,O
provided,O
to,O
the,O
environment,O
and,O
health,O
per,O
‐,O
sonnel,O
.,O
When,O
facing,O
patients,O
during,O
the,O
pandemic,O
lockdown,O
Always,O
keep,O
in,O
mind,O
that,O
the,O
main,O
goal,O
during,O
this,O
pandemic,O
is,O
to,O
pro,O
‐,O
tect,O
yourself,O
and,O
your,O
patient,O
.,O
preserve,O
all,O
health,O
services,O
to,O
stop,O
its,O
spread,O
.,O
and,O
prevent,O
the,O
health,O
system,O
from,O
being,O
compro,O
‐,O
mised,O
.,O
It,O
is,O
safer,O
to,O
divide,O
patients,O
who,O
attend,O
eye,O
clinics,O
or,O
have,O
ophthalmology,O
clinics,O
that,O
see,O
patients,O
should,O
be,O
equipped,O
with,O
screening,O
stations,O
before,O
entry,O
to,O
the,O
waiting,O
area,O
and,O
must,O
take,O
a,O
detailed,O
history,O
about,O
any,O
respiratory,O
illnesses,O
.,O
fever,CAUSE_OF_DEATH
.,O
recent,O
return,O
from,O
high,O
‐,O
risk,O
areas,O
.,O
or,O
contact,O
with,O
family,O
mem,O
‐,O
bers,O
recently,DATE
back,O
from,O
one,NUMBER
of,O
the,O
countries,O
battling,O
a,O
COVID,O
‐,O
19,NUMBER
outbreak,O
[,O
5,NUMBER
],O
.,O
This,O
way,O
.,O
every,O
patient,O
can,O
be,O
classified,O
as,O
low,O
.,O
medium,O
.,O
or,O
high,O
risk,O
.,O
This,O
should,O
be,O
coupled,O
with,O
nurse,TITLE
‐,O
directed,O
triage,O
protocols,O
to,O
determine,O
if,O
an,O
appointment,O
is,O
necessary,O
or,O
if,O
the,O
patient,O
can,O
reschedule,O
and,O
be,O
sent,O
home,O
to,O
ensure,O
safe,O
triage,O
and,O
isolation,O
of,O
patients,O
presenting,O
with,O
COVID,O
‐,O
19,NUMBER
symp,O
‐,O
toms,O
or,O
other,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
.,O
Those,O
at,O
low,O
risk,O
can,O
be,O
attended,O
to,O
with,O
standard,O
precautions,O
.,O
Medium,O
‐,O
risk,O
patients,O
with,O
non,O
‐,O
urgent,O
ophthalmic,O
problems,O
should,O
be,O
asked,O
to,O
return,O
home,O
and,O
reschedule,O
their,O
appointment,O
[,O
5,NUMBER
],O
.,O
High,O
‐,O
risk,O
patients,O
with,O
a,O
non,O
‐,O
urgent,O
ophthalmic,O
problem,O
should,O
be,O
sent,O
patients,O
with,O
urgent,O
ophthalmic,O
problems,O
should,O
be,O
put,O
in,O
the,O
examination,O
lane,O
immedi,O
‐,O
ately,O
in,O
order,O
to,O
decrease,O
the,O
time,O
spent,O
at,O
the,O
clinic,O
.,O
The,O
pa,O
‐,O
tient,O
.,O
the,O
ophthalmologist,TITLE
.,O
and,O
all,O
health,O
care,O
personnel,O
should,O
wear,O
surgical,O
masks,O
.,O
gowns,O
.,O
gloves,O
.,O
and,O
eye,O
protection,O
.,O
In,O
case,O
of,O
any,O
planned,O
procedure,O
that,O
results,O
in,O
an,O
aerosolized,O
virus,O
.,O
an,O
N95,O
mask,O
should,O
be,O
worn,O
.,O
Highrisk,O
or,O
COVID,O
‐,O
19,NUMBER
positive,O
patients,O
with,O
urgent,O
ophthalmic,O
problems,O
can,O
be,O
seen,O
but,O
after,O
following,O
local,O
hospital,O
guidelines,O
and,O
precautions,O
for,O
treating,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
or,O
that,O
of,O
the,O
Centers,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,O
Pre,O
‐,O
vention,O
(,O
CDC,ORGANIZATION
),O
such,O
as,O
using,O
an,O
N95,O
mask,O
.,O
eye,O
including,O
using,O
a,O
breath,O
shield,O
during,O
a,O
slit,O
‐,O
lamp,O
exam,O
or,O
any,O
clear,O
plastic,O
barri,O
‐,O
er,O
to,O
block,O
the,O
transfer,O
of,O
breaths,O
between,O
the,O
patient,O
and,O
the,O
doctor,TITLE
(,O
2,NUMBER
),O
.,O
Ophthalmologists,O
should,O
tell,O
their,O
patients,O
that,O
they,O
will,O
speak,O
as,O
little,O
as,O
possible,O
during,O
the,O
slit,O
‐,O
lamp,O
examination,O
and,O
request,O
that,O
the,O
patients,O
also,O
refrain,O
from,O
talking,O
.,O
They,O
should,O
always,O
use,O
protection,O
for,O
the,O
mouth,O
.,O
nose,O
.,O
and,O
eyes,O
when,O
caring,O
for,O
patients,O
potentially,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
They,O
should,O
also,O
keep,O
the,O
waiting,O
room,O
as,O
empty,O
as,O
possible,O
and,O
advise,O
seated,O
patients,O
to,O
remain,O
at,O
least,O
two,NUMBER
meters,O
(,O
around,O
6,NUMBER
feet,O
),O
from,O
one,NUMBER
another,O
[,O
5,NUMBER
],O
.,O
As,O
much,O
as,O
is,O
prudent,O
.,O
they,O
should,O
reduce,O
the,O
visits,O
of,O
the,O
most,O
vulnerable,O
patients,O
.,O
Patients,O
with,O
or,O
sus,O
‐,O
pected,O
to,O
have,O
COVID,O
‐,O
19,NUMBER
should,O
be,O
cared,O
for,O
in,O
a,O
single,O
‐,O
person,O
room,O
with,O
the,O
door,O
closed,O
.,O
Limited,O
points,O
of,O
entry,O
to,O
the,O
facili,O
‐,O
ty,O
is,O
strongly,O
recommended,O
too,O
.,O
No,O
symptoms,O
(,O
e.g,O
.,O
cough,O
.,O
fever,CAUSE_OF_DEATH
.,O
breathlessness,O
.,O
diarrhea,O
.,O
No,O
contact,O
with,O
someone,O
who,O
is,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
positive,O
.,O
No,O
stay,O
in,O
a,O
high,O
‐,O
risk,O
area,O
during,O
the,O
previous,O
14,DURATION
days,DURATION
Presence,O
of,O
symptoms,O
with,O
:,O
No,O
medical,O
history,O
or,O
contact,O
with,O
someone,O
who,O
is,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
positive,O
.,O
No,O
stay,O
in,O
a,O
high,O
‐,O
risk,O
area,O
during,O
the,DURATION
previous,DURATION
14,DURATION
days,DURATION
At,O
least,O
one,NUMBER
symptom,O
out,O
of,O
the,O
following,O
:,O
Contact,O
with,O
someone,O
who,O
is,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
positive,O
.,O
Stay,O
in,O
a,O
high,O
‐,O
risk,O
area,O
during,O
the,DURATION
previous,DURATION
14,DURATION
days,DURATION
TABLE,O
1,NUMBER
:,O
Risk,O
groups,O
and,O
symptoms,O
of,O
possible,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
infection,CAUSE_OF_DEATH
in,O
patients,O
seeing,O
at,O
an,O
ophthalmology,O
clinic,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
Reopening,O
the,O
ophthal,O
‐,O
mology,O
clinic,O
Before,O
opening,O
a,O
routine,O
clinic,O
.,O
checklist,O
criteria,O
that,O
aim,O
at,O
safe,O
opening,O
should,O
be,O
available,O
.,O
Complying,O
with,O
lo,O
‐,O
cal,O
governmental,O
guidance,O
.,O
these,O
guidelines,O
should,O
be,O
closely,O
the,O
success,O
of,O
your,O
practice,O
reopening,O
.,O
including,O
an,O
assessment,O
of,O
your,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
needs,O
and,O
alternatives,O
such,O
as,O
cloth,O
masks,O
.,O
eye,O
protection,O
.,O
and,O
others,O
[,O
8,NUMBER
],O
.,O
Evaluate,O
the,O
clinics,O
to,O
determine,O
what,O
kinds,O
of,O
surfaces,O
and,O
materials,O
make,O
up,O
that,O
area,O
.,O
as,O
most,O
surfaces,O
just,O
need,O
normal,O
.,O
routine,O
cleaning,O
;,O
however,O
.,O
frequently,O
touched,O
surfaces,O
like,O
doorknobs,O
will,O
need,O
to,O
be,O
cleaned,O
with,O
soap,O
and,O
water,O
and,O
then,O
disinfected,O
using,O
United,ORGANIZATION
States,ORGANIZATION
Environmental,ORGANIZATION
Protection,ORGANIZATION
Agency,ORGANIZATION
(,O
EPA,ORGANIZATION
),O
‐,O
ap,O
‐,O
proved,O
disinfectant,O
.,O
If,O
a,O
disinfectant,O
is,O
unavailable,O
.,O
you,O
can,O
use,O
one,NUMBER
‐,O
third,ORDINAL
cup,O
of,O
bleach,O
added,O
to,O
1,NUMBER
gallon,O
of,O
water,O
or,O
70,PERCENT
%,PERCENT
al,O
‐,O
cohol,O
solutions,O
to,O
staff,O
who,O
do,O
not,O
need,O
to,O
be,O
physically,O
present,DATE
in,O
the,O
office,O
stay,O
at,O
home,O
and,O
work,O
remotely,O
.,O
Even,O
more,O
.,O
consid,O
‐,O
er,O
bringing,O
employees,O
back,O
in,O
stages,O
.,O
at,O
different,O
parts,O
of,O
the,O
day,DURATION
.,O
or,O
working,O
on,O
alternative,O
days,DURATION
.,O
Start,O
with,O
a,O
few,O
outpatients,O
visits,O
a,DURATION
day,DURATION
and,O
work,O
on,O
a,O
modified,O
schedule,O
to,O
avoid,O
high,O
volume,O
or,O
density,O
.,O
Unless,O
necessary,O
.,O
ask,O
patients,O
to,O
attend,O
alone,O
.,O
keep,O
the,O
waiting,O
room,O
as,O
empty,O
as,O
possible,O
.,O
and,O
advise,O
seated,O
patients,O
to,O
remain,O
at,O
least,O
two,NUMBER
meters,O
(,O
around,O
6,NUMBER
feet,O
),O
from,O
one,NUMBER
another,O
.,O
consider,O
another,O
option,O
to,O
wait,O
in,O
the,O
clinic,O
by,O
asking,O
patients,O
to,O
wait,O
in,O
their,O
car,O
or,O
outside,O
and,O
text,O
or,O
calling,O
when,O
the,O
ap,O
‐,O
pointment,O
is,O
ready,O
.,O
Remove,O
magazines,O
.,O
brochures,O
.,O
remote,O
controls,O
.,O
and,O
other,O
shared,O
items,O
from,O
waiting,O
and,O
exam,O
rooms,O
.,O
Follow,O
U.S.,COUNTRY
Centers,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
(,O
CDC,ORGANIZATION
),O
guidance,O
.,O
which,O
requires,O
all,O
individuals,O
who,O
visit,O
the,O
office,O
to,O
wear,O
a,O
cloth,O
face,O
covering,O
.,O
This,O
should,O
be,O
explained,O
to,O
patients,O
and,O
other,O
visitors,O
before,O
they,O
arrive,O
at,O
the,O
clinic,O
.,O
Prioritize,O
seniors,O
above,O
60,DURATION
years,DURATION
.,O
those,O
with,O
chronic,O
diseases,CAUSE_OF_DEATH
like,O
diabetes,CAUSE_OF_DEATH
melli,O
‐,O
tus,O
.,O
and,O
patients,O
on,O
chemotherapy,O
to,O
be,O
seen,O
and,O
leave,O
the,O
clinic,O
early,O
.,O
The,O
availability,O
of,O
screening,O
stations,O
before,O
entry,O
to,O
the,O
waiting,O
area,O
should,O
also,O
continue,O
to,O
pick,O
up,O
any,O
suspected,O
cases,O
and,O
then,O
deal,O
with,O
them,O
as,O
high,O
‐,O
risk,O
patients,O
.,O
between,O
the,O
pa,O
‐,O
tient,O
and,O
the,O
doctor,TITLE
After,O
seeing,O
a,O
patient,O
After,O
seeing,O
every,O
patient,O
.,O
standard,O
cleaning,O
and,O
disinfection,O
should,O
apply,O
to,O
all,O
patient,O
care,O
.,O
regardless,O
of,O
the,O
suspected,O
or,O
confirmed,O
infection,CAUSE_OF_DEATH
status,O
of,O
the,O
patient,O
[,O
5,NUMBER
],O
.,O
Wear,O
single,O
‐,O
use,O
gloves,O
when,O
cleaning,O
and,O
disinfecting,O
surfaces,O
.,O
All,O
ophthalmic,O
instruments,O
.,O
including,O
slitlamps,O
.,O
tonometer,O
.,O
and,O
contact,O
lenses,O
.,O
and,O
all,O
places,O
the,O
pa,O
‐,O
tient,O
touched,O
should,O
be,O
disinfected,O
.,O
Standard,O
hand,O
hygiene,O
is,O
critical,O
.,O
including,O
frequent,O
hand,O
wash,O
with,O
soap,O
and,O
water,O
for,O
at,O
least,O
20,DURATION
seconds,DURATION
before,O
and,O
after,O
seeing,O
patients,O
[,O
8,NUMBER
],O
.,O
If,O
soap,O
and,O
water,O
are,O
not,O
readily,O
available,O
.,O
use,O
a,O
hand,O
sanitizer,O
that,O
contains,O
at,O
least,O
60,PERCENT
%,PERCENT
alcohol,O
[,O
5,NUMBER
],O
.,O
The,O
virus,O
causing,O
COVID,O
‐,O
19,NUMBER
is,O
an,O
enveloped,O
virus,O
.,O
making,O
it,O
very,O
susceptible,O
to,O
the,O
same,O
alco,O
‐,O
hol,O
‐,O
and,O
bleach,O
‐,O
based,O
disinfectants,O
that,O
ophthalmologists,O
common,O
‐,O
ly,O
use,O
to,O
disinfect,O
ophthalmic,O
instruments,O
and,O
office,O
furniture,O
.,O
Some,O
methods,O
recommended,O
by,O
the,O
CDC,ORGANIZATION
to,O
disinfect,O
and,O
destroy,O
the,O
COVID,O
‐,O
19,NUMBER
virus,O
include,O
alcohol,O
solutions,O
with,O
at,O
least,O
70,PERCENT
%,PERCENT
alco,O
‐,O
hol,O
and,O
diluted,O
bleach,O
.,O
However,O
.,O
the,O
United,COUNTRY
States,COUNTRY
Environmental,O
Protection,ORGANIZATION
Agency,ORGANIZATION
(,O
EPA,ORGANIZATION
),O
shared,O
a,O
list,O
of,O
antimicrobial,O
products,O
like,O
Stepan,ORGANIZATION
Company,ORGANIZATION
(,O
Northfield,CITY
.,O
Illinois,STATE_OR_PROVINCE
),O
products,O
(,O
disinfectant,O
spray,O
),O
that,O
are,O
expected,O
to,O
be,O
effective,O
against,O
COVID,O
‐,O
19,NUMBER
[,O
9,NUMBER
],O
.,O
The,O
importance,O
of,O
disinfecting,O
ophthalmic,O
examination,O
instruments,O
to,O
minimize,O
cross,O
‐,O
infections,CAUSE_OF_DEATH
and,O
protect,O
ophthalmic,O
medical,O
staff,O
is,O
clear,O
.,O
There,O
are,O
a,O
wide,O
range,O
of,O
disinfectants,O
available,O
that,O
can,O
be,O
used,O
to,O
disinfect,O
surfaces,O
.,O
Kampf,O
et,O
al,O
.,O
found,O
that,O
some,O
members,O
of,O
the,O
coronavirus,O
family,O
‐,O
SARS,O
and,O
Middle,LOCATION
East,LOCATION
respira,O
‐,O
tory,O
syndrome,O
(,O
MERS,O
),O
‐,O
can,O
persist,O
on,O
surfaces,O
like,O
metal,O
.,O
glass,O
.,O
or,O
plastic,O
for,O
up,DURATION
to,DURATION
nine,DURATION
days,DURATION
but,O
can,O
be,O
efficiently,O
inactivated,O
by,O
surface,O
disinfection,O
with,O
62,PERCENT
%,PERCENT
‐,O
71,PERCENT
%,PERCENT
ethanol,O
.,O
0.5,PERCENT
%,PERCENT
hydrogen,O
per,O
‐,O
oxide,O
.,O
or,O
0.1,PERCENT
%,PERCENT
sodium,O
hypochlorite,O
within,O
one,DURATION
minute,DURATION
.,O
Other,O
bio,O
‐,O
cidal,O
agents,O
.,O
such,O
as,O
0.05,PERCENT
%,PERCENT
to,O
0.2,PERCENT
%,PERCENT
benzalkonium,O
chloride,O
or,O
0.02,PERCENT
%,PERCENT
chlorhexidine,O
digluconate,O
.,O
are,O
less,O
effective,O
[,O
10,NUMBER
],O
.,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
and,O
possible,O
eye,O
involvement,O
Severe,O
acute,O
res,O
‐,O
piratory,O
syndrome,O
coronavirus,O
type,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
also,O
known,O
as,O
COVID,O
‐,O
19,NUMBER
virus,O
.,O
is,O
a,O
species,O
of,O
the,O
coronavirus,O
family,O
that,O
in,O
‐,O
fects,O
humans,O
.,O
bats,O
.,O
and,O
certain,O
other,O
mammals,O
.,O
In,O
fact,O
.,O
bats,O
are,O
a,O
major,O
reservoir,O
of,O
many,O
strains,O
of,O
SARS,O
‐,O
related,O
coronaviruses,O
.,O
and,O
several,O
strains,O
have,O
been,O
identified,O
in,O
palm,O
civets,O
.,O
which,O
were,O
likely,O
ancestors,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Cross,O
‐,O
species,O
transmission,O
(,O
CST,O
),O
.,O
also,O
called,O
host,TITLE
jump,O
.,O
or,O
spillover,O
.,O
is,O
the,O
ability,O
of,O
a,O
foreign,O
virus,O
.,O
once,DATE
introduced,O
into,O
a,O
new,O
host,TITLE
species,O
.,O
to,O
infect,O
that,O
individual,O
and,O
spread,O
throughout,O
the,O
new,O
host,TITLE
population,O
.,O
as,O
has,O
happened,O
with,O
swine,O
flu,CAUSE_OF_DEATH
.,O
SARS,O
‐,O
COV,O
‐,O
1,NUMBER
.,O
and,O
now,DATE
COVID,O
‐,O
19,NUMBER
[,O
11,NUMBER
],O
.,O
It,O
is,O
a,O
member,O
of,O
the,O
genus,O
betacoronavirus,O
and,O
subgenus,O
Sarbeco,O
‐,O
ronavirus,O
and,O
is,O
an,O
enveloped,O
positive,O
‐,O
sense,O
single,O
‐,O
stranded,O
RNA,O
virus,O
that,O
enters,O
its,O
host,TITLE
cell,O
by,O
binding,O
to,O
the,O
angiotensin,O
‐,O
converting,O
enzyme,O
2,NUMBER
receptor,O
(,O
ACE2,O
),O
receptor,O
[,O
12,NUMBER
],O
.,O
Human,O
to,O
human,O
transmission,O
occurs,O
with,O
close,O
contact,O
with,O
an,O
infected,O
person,O
.,O
This,O
primarily,O
occurs,O
when,O
an,O
infected,O
person,O
coughs,O
or,O
sneezes,O
and,O
produces,O
respiratory,O
droplets,O
that,O
spread,O
like,O
other,O
respira,O
‐,O
tory,O
pathogens,O
.,O
These,O
droplets,O
can,O
settle,O
in,O
the,O
mouth,O
or,O
nasal,O
mucosa,O
and,O
lungs,O
of,O
people,O
who,O
inhale,O
the,O
air,O
[,O
13,NUMBER
],O
.,O
However,O
.,O
it,O
is,O
widely,O
agreed,O
that,O
the,O
clinical,O
picture,O
varies,O
from,O
a,O
simple,O
respiratory,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
.,O
which,O
presents,O
with,O
symptoms,O
such,O
as,O
a,O
runny,O
nose,O
.,O
sore,O
throat,O
.,O
fever,CAUSE_OF_DEATH
.,O
and,O
coughing,O
to,O
more,O
complicated,O
findings,O
like,O
septic,O
shock,O
[,O
14,NUMBER
],O
.,O
Similar,O
to,O
SARS,O
‐,O
CoV,O
and,O
MERS,O
‐,O
CoV,O
.,O
which,O
caused,O
epidemics,O
in,O
the,DATE
past,DATE
years,DATE
.,O
the,O
usual,O
first,ORDINAL
symptoms,O
are,O
commonly,O
defined,O
as,O
fever,CAUSE_OF_DEATH
.,O
cough,O
.,O
and,O
shortness,O
of,O
breath,O
.,O
In,O
99,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
virus,O
infection,CAUSE_OF_DEATH
.,O
chest,O
pain,O
.,O
confusion,O
.,O
and,O
nausea,O
‐,O
vomiting,O
were,O
noted,O
in,O
addition,O
to,O
previous,O
findings,O
[,O
15,NUMBER
],O
.,O
X,O
‐,O
ray,O
and,O
thorax,O
CT,STATE_OR_PROVINCE
imaging,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
showed,O
unilateral,O
or,O
bilateral,O
involvement,O
compatible,O
with,O
viral,O
pneumonia,CAUSE_OF_DEATH
.,O
Reported,O
complications,CAUSE_OF_DEATH
include,O
acute,O
heart,O
damage,O
.,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
.,O
secondary,O
in,O
‐,O
fections,O
.,O
pneumothorax,O
.,O
and,O
some,O
patients,O
with,O
other,O
comorbidity,O
exhibited,O
more,O
severe,O
symptoms,O
and,O
even,O
death,O
[,O
16,NUMBER
],O
.,O
The,O
diagnosis,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
is,O
based,O
on,O
history,O
.,O
including,O
detailed,O
contact,O
and,O
travel,O
history,O
aided,O
by,O
laboratory,O
testing,O
.,O
Viral,O
in,O
‐,O
fection,O
laboratory,O
testing,O
methods,O
are,O
important,O
.,O
including,O
serology,O
tests,O
and,O
viral,O
culture,O
.,O
The,O
most,O
commonly,O
used,O
diagnos,O
‐,O
tic,O
methods,O
are,O
molecular,O
methods,O
.,O
such,O
as,O
reverse,O
transcription,O
‐,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
‐,O
PCR,O
),O
or,O
real,O
‐,O
time,O
PCR,O
by,O
using,O
a,O
respiratory,O
sample,O
as,O
the,O
oropharyngeal,O
swab,O
.,O
sputum,O
.,O
or,O
bron,O
‐,O
choalveolar,O
lavage,O
.,O
Unfortunately,O
.,O
the,O
COVID,O
‐,O
19,NUMBER
virus,O
not,O
only,O
affects,O
the,O
respiratory,O
tracts,O
.,O
it,O
also,O
may,O
manifest,O
in,O
other,O
re,O
‐,O
gions,O
like,O
the,O
gastrointestinal,O
tract,O
and,O
ocular,O
tissues,O
.,O
as,O
con,O
‐,O
junctivitis,O
has,O
been,O
reported,O
during,O
this,O
outbreak,O
and,O
conjuncti,O
‐,O
val,O
secretions,O
yielded,O
positive,O
RT,O
‐,O
PCR,O
results,O
[,O
17,NUMBER
],O
.,O
This,O
sug,O
‐,O
gests,O
that,O
COVID,O
‐,O
19,NUMBER
can,O
infect,O
the,O
conjunctiva,O
and,O
cause,O
conjunc,O
‐,O
tivitis,O
.,O
and,O
virus,O
family,O
can,O
occasionally,O
cause,O
conjunctivitis,O
in,O
humans,O
.,O
In,O
fact,O
.,O
human,O
coronavirus,O
NL,STATE_OR_PROVINCE
63,NUMBER
(,O
HCoV,O
‐,O
NL63,O
),O
was,O
first,ORDINAL
identified,O
in,O
a,O
baby,O
with,O
bronchiolitis,O
and,O
conjunctivitis,O
.,O
In,O
28,NUMBER
cases,O
of,O
children,O
with,O
confirmed,O
HCoV,O
‐,O
NL63,O
infections,CAUSE_OF_DEATH
.,O
17,PERCENT
%,PERCENT
had,O
conjunctivitis,O
[,O
18,NUMBER
],O
.,O
Clinical,O
entities,O
.,O
such,O
as,O
conjunctivitis,O
.,O
anterior,O
uveitis,O
.,O
retinitis,O
.,O
and,O
optic,O
neuritis,O
.,O
have,O
been,O
seen,O
in,O
animal,O
models,O
[,O
19,NUMBER
],O
.,O
One,NUMBER
of,O
the,O
affected,O
healthcare,O
workers,O
re,O
‐,O
ported,O
his,O
experience,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
Despite,O
being,O
fully,O
dressed,O
in,O
a,O
protective,O
suit,O
and,O
N95,MISC
respirator,O
.,O
he,O
was,O
still,O
in,O
‐,O
fected,O
by,O
the,O
virus,O
.,O
with,O
the,O
first,ORDINAL
symptom,O
being,O
unilateral,O
con,O
‐,O
junctivitis,O
.,O
followed,O
by,O
fever,CAUSE_OF_DEATH
.,O
In,O
spite,O
of,O
the,O
controversy,O
about,O
the,O
eye,O
as,O
the,O
possible,O
means,O
of,O
transmitting,O
disease,CAUSE_OF_DEATH
.,O
Qing,O
et,O
al.,O
posit,O
that,O
the,O
virus,O
enters,O
the,O
tear,O
duct,O
through,O
droplets,O
.,O
which,O
may,O
pass,O
through,O
the,O
nasolacrimal,O
ducts,O
and,O
then,O
into,O
the,O
respiratory,O
tract,O
[,O
20,NUMBER
],O
.,O
Combined,O
with,O
all,O
this,O
information,O
.,O
we,O
assert,O
that,O
healthcare,O
professionals,O
should,O
use,O
eye,O
protection,O
when,O
in,O
close,O
contact,O
with,O
patients,O
.,O
At,O
the,O
time,DATE
of,O
the,O
pandem,O
‐,O
ic,O
.,O
with,O
limited,O
information,O
.,O
no,O
treatment,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
and,O
no,O
vaccine,O
as,O
yet,O
.,O
we,O
will,O
need,O
to,O
stay,O
highly,O
cautious,O
to,O
recognize,O
the,O
possible,O
non,O
‐,O
respiratory,O
early,O
manifestations,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
‐,O
fection,O
.,O
including,O
the,O
consideration,O
of,O
viral,O
conjunctivitis,O
as,O
a,O
possible,O
presentation,O
.,O
Healthcare,O
professionals,O
.,O
including,O
oph,O
‐,O
thalmologists,O
.,O
should,O
take,O
the,O
full,O
recommended,O
measures,O
and,O
pre,O
‐,O
cautions,O
to,O
protect,O
themselves,O
and,O
their,O
patients,O
and,O
stop,O
the,O
spread,O
of,O
the,O
infection,CAUSE_OF_DEATH
.,O
Additional,O
Information,O
involve,O
animal,O
subjects,O
or,O
tissue,O
.,O
Conflicts,O
of,O
interest,O
:,O
In,O
compliance,O
with,O
the,O
ICMJE,O
uniform,O
declared,O
that,O
no,O
financial,O
support,O
was,O
received,O
from,O
any,O
organization,O
for,O
the,O
submitted,O
work,O
.,O
present,DATE
or,O
within,O
the,DURATION
previous,DURATION
three,DURATION
years,DURATION
with,O
any,O
organizations,O
that,O
might,O
have,O
an,O
interest,O
in,O
relationships,O
or,O
activities,O
that,O
could,O
appear,O
to,O
have,O
influenced,O
the,O
submitted,O
work,O
.,O
Nair,ORGANIZATION
AG,ORGANIZATION
.,O
Gandhi,PERSON
AR,PERSON
.,O
Sundaram,PERSON
N,O
:,O
Effect,O
of,O
COVID,O
‐,O
19,NUMBER
related,O
lockdown,O
on,O
ophthalmic,O
practice,O
and,O
patient,O
care,O
in,O
India,COUNTRY
:,O
results,O
of,O
a,O
survey,O
.,O
Indian,NATIONALITY
J,PERSON
Ophthalmol,PERSON
.,O
2020,DATE
.,O
68:725,NUMBER
‐,O
730,NUMBER
.,O
Lu,PERSON
CW,PERSON
.,O
Liu,PERSON
XF,O
.,O
Jia,O
Z,O
‐,O
F,O
:,O
2019,DATE
‐,O
nCoV,O
transmission,O
through,O
the,O
ocular,O
surface,O
must,O
not,O
be,O
ignored,O
.,O
Lancet,O
.,O
2020,DATE
.,O
395,NUMBER
:,O
e39,O
.,O
10.1016,NUMBER
/,O
S0140,O
‐,O
6736,NUMBER
(,O
20,NUMBER
),O
30313,NUMBER
‐,O
5,NUMBER
MD,ORGANIZATION
PNC,ORGANIZATION
.,O
MD,STATE_OR_PROVINCE
PMZ,O
.,O
PhD,O
XD,NUMBER
.,O
et,O
al.,O
:,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
99,NUMBER
cases,O
of,O
2019,DATE
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
descriptive,O
study,O
.,O
Lancet,O
.,O
2020,DATE
.,O
American,ORGANIZATION
Academy,ORGANIZATION
of,ORGANIZATION
Ophthalmology,ORGANIZATION
.,O
Important,O
coronavirus,O
updates,O
for,O
ophthalmologists,O
.,O
(,O
American,NATIONALITY
Academy,MISC
of,O
Ophthalmology,O
.,O
Important,O
coronavirus,O
updates,O
for,O
ophthalmolo,O
‐,O
gists,O
),O
.,O
Lai,MISC
THT,MISC
.,O
Tang,O
EWH,O
.,O
Chau,LOCATION
SKY,LOCATION
.,O
Fung,ORGANIZATION
KSC,ORGANIZATION
.,O
Li,PERSON
KKW,PERSON
:,O
Stepping,O
up,O
infection,CAUSE_OF_DEATH
control,O
measures,O
in,O
ophthalmology,O
during,O
the,O
novel,O
coronavirus,O
outbreak,O
:,O
an,O
experience,O
from,O
Hong,CITY
Kong,CITY
.,O
Graefes,PERSON
Arch,PERSON
Clin,O
Exp,O
Ophthalmol,O
.,O
2020,DATE
.,O
258:1049,NUMBER
‐,O
1055,DATE
.,O
10.1007,NUMBER
/,O
s00417,NUMBER
‐,O
020,NUMBER
‐,O
04641,NUMBER
‐,O
8,NUMBER
Repici,O
A,O
.,O
Maselli,PERSON
R,O
.,O
Colombo,CITY
M,O
.,O
Az,LOCATION
‐,O
zolini,O
E,O
.,O
Lagioia,O
M,O
:,O
Coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
outbreak,O
:,O
what,O
the,O
department,O
of,O
endoscopy,O
should,O
know,O
.,O
Gastrointest,O
Endosc,O
.,O
2020,DATE
.,O
92:192,NUMBER
‐,O
197,NUMBER
.,O
American,ORGANIZATION
Medical,ORGANIZATION
Association,ORGANIZATION
.,O
COVID,O
‐,O
19,NUMBER
:,O
A,O
physician,TITLE
practice,O
guide,TITLE
to,O
reopening,O
.,O
Updated,O
.,O
Kampf,O
G,O
.,O
Todt,PERSON
D,PERSON
.,O
Pfaender,PERSON
S,O
.,O
Steinmann,PERSON
E,O
:,O
Persistence,O
of,O
coronaviruses,O
on,O
inanimate,O
sur,O
‐,O
faces,O
and,O
its,O
inactivation,O
with,O
biocidal,O
agents,O
.,O
J,O
Hosp,O
Infect,O
.,O
2020,DATE
.,O
104:246,NUMBER
‐,O
251,NUMBER
.,O
Hilds,ORGANIZATION
JE,ORGANIZATION
.,O
Mackenzie,PERSON
JE,PERSON
.,O
Richt,PERSON
JE,O
:,O
Wildlife,O
and,O
emerging,O
zoonotic,O
diseases,CAUSE_OF_DEATH
:,O
the,O
biology,O
.,O
circumstances,O
and,O
consequences,O
of,O
cross,O
‐,O
species,O
transmission,O
.,O
Current,DATE
Topics,O
in,O
Ge,O
XY,O
.,O
Li,PERSON
JL,PERSON
.,O
Yang,PERSON
XL,O
.,O
et,O
al.,O
:,O
Isolation,O
and,O
characterization,O
of,O
a,O
bat,O
SARS,O
‐,O
like,O
coronavirus,O
that,O
uses,O
the,O
ACE2,O
receptor,O
.,O
Nature,O
.,O
2013,DATE
.,O
503:535,NUMBER
‐,O
538,NUMBER
.,O
Li,PERSON
J,PERSON
‐,O
Y,O
.,O
You,O
Z,O
.,O
Wang,O
Q,O
.,O
et,O
al.,O
:,O
The,O
epidemic,O
of,O
2019,DATE
‐,O
novel,O
‐,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
pneumonia,CAUSE_OF_DEATH
and,O
insights,O
for,O
emerging,O
infectious,O
diseases,CAUSE_OF_DEATH
in,O
the,DATE
future,DATE
.,O
Microbes,O
Infect,O
.,O
2020,DATE
.,O
Cipriano,PERSON
M,O
.,O
Ruberti,PERSON
E,O
.,O
Giacalone,PERSON
A,O
:,O
Gastrointestinal,O
infec,O
‐,O
tion,O
could,O
be,O
new,O
focus,O
for,O
coronavirus,O
diagnosis,O
.,O
Cureus,MISC
.,O
2020,DATE
.,O
12,NUMBER
:,O
e7422,O
.,O
10.7759,NUMBER
/,O
cureus,O
.7422,NUMBER
Chen,O
N,O
.,O
Zhou,PERSON
M,O
.,O
Dong,PERSON
X,PERSON
.,O
et,O
al.,O
:,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
99,NUMBER
cases,O
of,O
2019,DATE
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
descriptive,O
study,O
.,O
Lancet,O
.,O
2020,DATE
.,O
Huang,PERSON
C,PERSON
.,O
Wang,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
et,O
al.,O
:,O
Clinical,O
features,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coronavirus,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Lancet,O
.,O
2020,DATE
.,O
395:497,NUMBER
‐,O
506,NUMBER
.,O
10.1016,NUMBER
/,O
S0140,O
‐,O
6736,NUMBER
(,O
20,NUMBER
),O
30183,NUMBER
‐,O
5,NUMBER
Xia,PERSON
J,PERSON
.,O
Tong,PERSON
J,PERSON
.,O
Liu,PERSON
M,O
.,O
Shen,O
Y,O
.,O
Guo,PERSON
D,O
:,O
Evaluation,O
of,O
coronavirus,O
in,O
tears,O
and,O
conjunctival,O
secretions,O
of,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
.,O
J,PERSON
Med,PERSON
Virol,PERSON
.,O
2020,DATE
.,O
92:589,NUMBER
‐,O
594,NUMBER
.,O
Vabret,O
A,O
.,O
Mourez,PERSON
T,PERSON
.,O
Dina,PERSON
J,PERSON
.,O
et,O
al.,O
:,O
Human,O
coronavirus,O
NL63,O
.,O
France,COUNTRY
.,O
Emerg,O
Infect,O
Dis,O
.,O
2005,DATE
.,O
coronaviruses,O
and,O
ocular,O
implications,O
in,O
humans,O
and,O
animals,O
.,O
Ocul,PERSON
Immunol,O
Inflamm,O
.,O
2020,DATE
.,O
Qing,O
H,O
.,O
Li,PERSON
Z,PERSON
.,O
Yang,PERSON
Z,PERSON
.,O
Shi,O
M,O
.,O
Huang,PERSON
Z,PERSON
.,O
Song,O
J,O
.,O
Song,O
Z,O
:,O
The,O
possibility,O
of,O
COVID,O
‐,O
19,NUMBER
transmission,O
from,O
eye,O
to,O
nose,O
.,O
Acta,PERSON
Ophthalmologica,PERSON
.,O
2020,DATE
.,O
98,NUMBER
:,O
e388,O
.,O
10.1111,NUMBER
/,O
aos,O
.14412,NUMBER
